First Guidelines for Providing Oncology Pharmacy Services in COVID-19
The first set of guidelines for providing oncology pharmacy services to cancer patients during the COVID-19 pandemic was recently published.
News
Latest News
Xpovio Approved for Relapsed/Refractory Diffuse Large B-Cell Lymphoma
The FDA has granted accelerated approval of Xpovio® (selinexor; Karyopharm) for the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL), not otherwise specified, including DLBCL arising from follicular lymphoma, after at least 2 lines of systemic therapy.
Bodyweight-Based Dosing of Nivolumab Results in Wastage
A review of practices prior to a change in nivolumab dosing demonstrated that bodyweight dosing resulted in a 6.1% rate of wastage at a significant cost compared with a fixed dose of 240 mg per dose.
Antidiabetic Medication Adherence, Survival for Patients With Diabetes and Colorectal Cancer
Researchers assessed whether adherence to oral antidiabetic medication was a modifiable prognostic factor in patients with CRC and preexisting diabetes.
Neoadjuvant Chemotherapy Increases Immunogenicity of High-Grade Serous Ovarian Cancer
This study sought to address outstanding questions regarding tumor heterogeneity in the setting of HGSOC, including its relationship with treatment response.
Acquired ESR1 Mutations Predict Poor Benefit from Further AI Therapy in Metastatic Breast Cancer
The detection of acquired ESR1 mutations in patients with hormone receptor (HR) positive metastatic breast cancer predicted poor clinical benefit from exemestane.
Tazverik Granted Accelerated Approval for Follicular Lymphoma
Tazverik, a methyltransferase inhibitor, is already indicated for the treatment of patients aged ≥16 years with metastatic or locally advanced epithelioid sarcoma not eligible for complete resection.
Crysvita Approved for Treatment of Tumor-Induced Osteomalacia
The FDA has approved Crysvita® (burosumab-twza; Ultragenyx) for the treatment of fibroblast growth factor 23 (FGF23)-related hypophosphatemia in tumor-induced osteomalacia associated with phosphaturic mesenchymal tumors that cannot be curatively resected or localized in patients aged ≥2 years.
Expert Panel Provides Guidance on Prostate Cancer Genetic Testing
A panel of experts agreed that men with metastatic prostate cancer may be the most appropriate candidates for comprehensive genetic testing.
Higher Levels of Outdoor Light at Night May Be Linked to Increased Breast Cancer Risk
The incidence of breast cancer for postmenopausal women included in the NIH-AARP study was evaluated with respect to level of outdoor light at night.
Immunoradiotherapy May Be a Promising Option in Cisplatin-Ineligible Head and Neck Cancer
Preclinical data has suggested that radiotherapy can increase sensitivity to immunotherapy and that immunotherapy can sensitize cancer cells to radiation.
US Medical Cancer Care Costs Substantial, Expected to Increase
Costs of care for patients with cancer was found to vary based on stage and site of disease.
FGFR Inhibitor, AZD4547, Misses Primary Endpoint in NCI-MATCH Trial
The NCI-MATCH trial is evaluating targeted therapies in multiple subprotocols for patients with tumors characterized by potentially targetable driver alterations.
Study: Template-Based LND May Aid Local UTUC Control
Template-based lymph node dissection in patients with upper tract urothelial carcinoma could facilitate better local disease control by eliminating micrometastasis, according to investigators.
Study Investigates Association Between Height and Risk of Invasive Melanoma
This study used data from the Nurses’ Health Study (NHS) and NHS2 to explore the association between height, number of nevi, and risk of invasive melanoma.
Want to read more?
Please login or register first to view this content.
Next post in EHA25 Virtual Congress
